CA3080402A1 - Aminoimidazopyridazines as kinase inhibitors - Google Patents

Aminoimidazopyridazines as kinase inhibitors Download PDF

Info

Publication number
CA3080402A1
CA3080402A1 CA3080402A CA3080402A CA3080402A1 CA 3080402 A1 CA3080402 A1 CA 3080402A1 CA 3080402 A CA3080402 A CA 3080402A CA 3080402 A CA3080402 A CA 3080402A CA 3080402 A1 CA3080402 A1 CA 3080402A1
Authority
CA
Canada
Prior art keywords
aminoimidazopyridazines
kinase inhibitors
diastereomers
stereoisomers
enantiomers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3080402A
Other languages
English (en)
French (fr)
Inventor
Michael E. Mertzman
Carolyn Diane Dzierba
Jason M. Guernon
Amy C. HART
Guanglin Luo
John E. Macor
William J. Pitts
Jianliang Shi
Steven H. Spergel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CA3080402A1 publication Critical patent/CA3080402A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3080402A 2017-10-30 2018-10-29 Aminoimidazopyridazines as kinase inhibitors Pending CA3080402A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762578607P 2017-10-30 2017-10-30
US62/578,607 2017-10-30
US201862626853P 2018-02-06 2018-02-06
US62/626,853 2018-02-06
PCT/US2018/057968 WO2019089442A1 (en) 2017-10-30 2018-10-29 Aminoimidazopyridines as kinase inhibitors

Publications (1)

Publication Number Publication Date
CA3080402A1 true CA3080402A1 (en) 2019-05-09

Family

ID=64332173

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3080402A Pending CA3080402A1 (en) 2017-10-30 2018-10-29 Aminoimidazopyridazines as kinase inhibitors

Country Status (23)

Country Link
US (1) US11440913B2 (enExample)
EP (1) EP3704118B1 (enExample)
JP (1) JP7228586B2 (enExample)
KR (1) KR102662197B1 (enExample)
CN (1) CN111566103B (enExample)
AU (1) AU2018361249B2 (enExample)
BR (1) BR112020007557A2 (enExample)
CA (1) CA3080402A1 (enExample)
CY (1) CY1124984T1 (enExample)
DK (1) DK3704118T3 (enExample)
ES (1) ES2905948T3 (enExample)
HR (1) HRP20220297T1 (enExample)
HU (1) HUE058292T2 (enExample)
IL (1) IL274207B2 (enExample)
LT (1) LT3704118T (enExample)
MX (1) MX2020003706A (enExample)
PL (1) PL3704118T3 (enExample)
PT (1) PT3704118T (enExample)
RS (1) RS62974B1 (enExample)
SG (1) SG11202003824PA (enExample)
SI (1) SI3704118T1 (enExample)
SM (1) SMT202200087T1 (enExample)
WO (1) WO2019089442A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2902676T3 (es) 2017-02-13 2022-03-29 Bristol Myers Squibb Co Aminotriazolopiridinas como inhibidores de cinasa
CA3088548A1 (en) 2018-01-26 2019-08-01 Bristol-Myers Squibb Company Aminopyrrolotriazines as kinase inhibitors
BR112021004310A2 (pt) 2018-09-13 2021-05-25 Bristol-Myers Squibb Company indazolcarboxamidas como inibidores de cinase
BR112021004385A2 (pt) 2018-09-13 2021-07-20 Bristol-Myers Squibb Company 1h-indazol carboxamidas como inibidores de proteína quinase de interação com o receptor 1 (ripk1)
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
US12275721B2 (en) 2019-10-03 2025-04-15 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
WO2021168521A1 (en) * 2020-02-27 2021-09-02 Anaxis Pharma Pty Ltd Inhibitors of necroptosis
CN114262322A (zh) * 2020-09-16 2022-04-01 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
WO2022081522A1 (en) 2020-10-13 2022-04-21 The Johns Hopkins University SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF
AR123793A1 (es) * 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas
CN120530112A (zh) * 2022-12-30 2025-08-22 广州市联瑞制药有限公司 双环类化合物及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
US7820665B2 (en) * 2007-12-19 2010-10-26 Amgen Inc. Imidazopyridazine inhibitors of PI3 kinase for cancer treatment
CA2750517A1 (en) * 2009-02-04 2010-08-12 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
BR112014030147B1 (pt) 2012-06-22 2019-10-15 Sumitomo Chemical Company, Limited Compostos heterocíclicos fundidos, composição e método para controlar pestes
EP2897949B1 (en) 2012-09-18 2018-01-10 Bristol-Myers Squibb Company Iap antagonists
ES2749467T3 (es) 2012-11-20 2020-03-20 Biogen Ma Inc Agentes moduladores de S1p y/o ATX
EP2970266B1 (en) 2013-03-15 2018-01-31 Epizyme, Inc. 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof
CN105246891A (zh) 2013-06-10 2016-01-13 拜耳制药股份公司 用于治疗癌症的新化合物
WO2016027253A1 (en) 2014-08-21 2016-02-25 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as rip1 kinase inhibitors as medicaments
WO2017192930A1 (en) 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
WO2018017435A1 (en) 2016-07-22 2018-01-25 Accro Bioscience Inc. Heteroaryl compounds as inhibitors of necrosis, composition and application thereof
ES2902676T3 (es) 2017-02-13 2022-03-29 Bristol Myers Squibb Co Aminotriazolopiridinas como inhibidores de cinasa
CA3088548A1 (en) 2018-01-26 2019-08-01 Bristol-Myers Squibb Company Aminopyrrolotriazines as kinase inhibitors
BR112021004385A2 (pt) 2018-09-13 2021-07-20 Bristol-Myers Squibb Company 1h-indazol carboxamidas como inibidores de proteína quinase de interação com o receptor 1 (ripk1)
BR112021004310A2 (pt) 2018-09-13 2021-05-25 Bristol-Myers Squibb Company indazolcarboxamidas como inibidores de cinase
EP3877371A4 (en) * 2018-11-07 2022-07-27 Dana-Farber Cancer Institute, Inc. IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES USED AS JANUS KINASE 2 INHIBITORS AND ASSOCIATED USES

Also Published As

Publication number Publication date
IL274207B2 (en) 2023-04-01
JP2021501179A (ja) 2021-01-14
SMT202200087T1 (it) 2022-03-21
BR112020007557A2 (pt) 2020-09-24
PL3704118T3 (pl) 2022-04-04
HRP20220297T1 (hr) 2022-05-13
US20200277296A1 (en) 2020-09-03
AU2018361249A1 (en) 2020-06-11
RS62974B1 (sr) 2022-03-31
KR102662197B1 (ko) 2024-04-29
CN111566103B (zh) 2023-06-23
MX2020003706A (es) 2020-07-22
EP3704118A1 (en) 2020-09-09
SI3704118T1 (sl) 2022-04-29
LT3704118T (lt) 2022-02-25
CN111566103A (zh) 2020-08-21
AU2018361249B2 (en) 2022-08-25
WO2019089442A8 (en) 2019-06-27
JP7228586B2 (ja) 2023-02-24
HUE058292T2 (hu) 2022-07-28
KR20200078591A (ko) 2020-07-01
EP3704118B1 (en) 2022-01-12
CY1124984T1 (el) 2023-01-05
SG11202003824PA (en) 2020-05-28
IL274207B (en) 2022-12-01
IL274207A (en) 2020-06-30
DK3704118T3 (da) 2022-03-14
ES2905948T3 (es) 2022-04-12
WO2019089442A1 (en) 2019-05-09
PT3704118T (pt) 2022-02-14
US11440913B2 (en) 2022-09-13

Similar Documents

Publication Publication Date Title
WO2019089442A8 (en) Aminoimidazopyridazines as kinase inhibitors
CY1124978T1 (el) Αμινοτριαζολοπυριμιδινες ως αναστολεις κινασων
MX2021002617A (es) Indazol carboxamidas como inhibidores de cinasas.
TN2011000274A1 (en) Carbazole carboxamide compounds useful as kinase inhibitors
WO2020010143A8 (en) Nlrp modulators
WO2018195439A3 (en) K-ras modulators
MY198004A (en) Antitumoral compounds
MX2021002509A (es) 1h-indazol carboxamidas como inhibidores de proteina cinasa de interaccion con receptor 1 (ripk1).
EP4335439A3 (en) Compounds
AU2018258581A8 (en) RAF-degrading conjugate compounds
ZA202101788B (en) Aminopyrimidine/pyrazine derivatives as ctps1 inhibitors
PH12017502090A1 (en) Heterocyclic amides as kinase inhibitors
WO2018195397A3 (en) Indole ahr inhibitors and uses thereof
WO2019145726A9 (en) Compounds
EP4635568A3 (en) Compounds, salts thereof and methods for treatment of diseases
CA3254823A1 (en) HETEROCYCLIC COMPOUNDS USEFUL FOR MODULATING BAF COMPLEXES
WO2019035865A8 (en) MODULATORS OF PYRUVATE KINASE AND THEIR USE
AU2018293627A1 (en) New azaquinoline derivatives
MX2022003769A (es) Indazol carboxamidas como inhibidores de cinasas.
MX388026B (es) Compuestos y métodos para modular la tirosina cinasa de bruton.
PH12018502233A1 (en) ErbB INHIBITORS AND USES THEREOF
NZ725417A (en) New sulfonylaminobenzamide compounds
WO2019094552A8 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
WO2019109067A3 (en) Creatine prodrugs, compositions and methods of use thereof
NZ728623A (en) Novel sulfonylaminobenzamide compounds as anthelmintics